Efficacy of Eimeria tenella rhomboid-like protein as a subunit vaccine in protective immunity against homologous challenge

Efficacy of Eimeria tenella rhomboid-like protein as a subunit vaccine in protective immunity against homologous challenge
复制标题

柔嫩艾美耳球菱形蛋白作为亚单位疫苗在针对同源攻击的保护性免疫中的功效

DOI:
10.1007/s00436-011-2603-1
复制
发表时间:
2012-03-01
影响因子:
2
通讯作者:
Zhang, Xichen
Zhang, Xichen
中科院分区:
医学3区
文献类型:
--
作者:
Li, Jianhua;Zheng, Jun;Zhang, Xichen

文献摘要

被引文献

相似文献

本文研究了柔嫩艾美耳球虫类菱形基因重组蛋白(ETRHO1)在鸡体内诱导的免疫应答和对同源攻击的保护作用。重组菱形抗原免疫鸡后,可产生特异性抗体。与PBS组相比,重组菱形蛋白免疫组IL-2、干扰素-γ的表达水平及CD_4~+、CD_8~+细胞百分率均显著升高(p < 0.01,p < 0.05,p < 0.05)。这些结果表明,菱形蛋白能够诱导禽类产生体液免疫和细胞免疫反应。攻毒试验表明,重组菱形蛋白可为鸡提供约77.3%的保护率。与PBS组相比,重组菱形蛋白免疫组雏鸡的卵囊数和盲肠病变数显著减少,体重显著增加(p < 0.05)。这些结果表明,重组菱形抗原能够对鸡的同源攻击产生部分保护作用,有可能成为研制柔嫩艾美耳球虫疫苗的候选疫苗。
The immune responses and protective efficacy against homologous challenge in chickens elicited by recombinant proteins of a rhomboid-like gene (ETRHO1) from Eimeria tenella was investigated in the present study. When chickens were immunized with the recombinant rhomboid antigen, specific antibody was generated by ELISA assay. In comparison with the PBS group, the expression levels of interleukin-2, interferon-γ, as well as the percentages of CD4+ and CD8+ cells in the group immunized with the recombinant rhomboid proteins were significantly increased (p < 0.01, p < 0.05, and p < 0.05, respectively). These results suggest that rhomboid was capable of eliciting humoral and cell-mediated immunity response in birds. Challenge experiments demonstrated that the recombinant rhomboid protein could provide chickens with a protection rate around 77.3%. Numbers of oocysts and cecal lesion from chickens in the group immunized with recombinant rhomboid proteins decreased significantly, and the body weight increased significantly when compared with chickens in the PBS group (p < 0.05). These results suggested that the recombinant rhomboid antigen was able to impart partial protection against homologous challenge in chicken and could be a potential candidate for an E. tenella vaccine development.